These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 25722088)
1. The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity. Hess C; Neri D Cancer Immunol Immunother; 2015 May; 64(5):635-44. PubMed ID: 25722088 [TBL] [Abstract][Full Text] [Related]
2. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6. Hess C; Neri D Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343 [TBL] [Abstract][Full Text] [Related]
3. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer. Hemmerle T; Neri D Int J Cancer; 2014 Jan; 134(2):467-77. PubMed ID: 23818211 [TBL] [Abstract][Full Text] [Related]
4. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354 [TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy. Pretto F; Elia G; Castioni N; Neri D Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857 [TBL] [Abstract][Full Text] [Related]
6. Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains. De Luca R; Neri D Cancer Immunol Immunother; 2018 Sep; 67(9):1381-1391. PubMed ID: 29971465 [TBL] [Abstract][Full Text] [Related]
7. Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression. Stringhini M; Mock J; Fontana V; Murer P; Neri D MAbs; 2021; 13(1):1868066. PubMed ID: 33404287 [TBL] [Abstract][Full Text] [Related]
9. The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo. Hemmerle T; Neri D Cancer Immunol Res; 2014 Jun; 2(6):559-67. PubMed ID: 24795141 [TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of calreticulin to ED-A fibronectin leads to tumor-growth retardation. Ziffels B; Grötsch A; Al-Bayati L; Neri D J Biotechnol; 2019 Jan; 290():53-58. PubMed ID: 30579890 [TBL] [Abstract][Full Text] [Related]
11. Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse. Doll F; Schwager K; Hemmerle T; Neri D Arthritis Res Ther; 2013 Sep; 15(5):R138. PubMed ID: 24289726 [TBL] [Abstract][Full Text] [Related]
12. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Schwager K; Kaspar M; Bootz F; Marcolongo R; Paresce E; Neri D; Trachsel E Arthritis Res Ther; 2009; 11(5):R142. PubMed ID: 19781067 [TBL] [Abstract][Full Text] [Related]
13. The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity. Hemmerle T; Probst P; Giovannoni L; Green AJ; Meyer T; Neri D Br J Cancer; 2013 Sep; 109(5):1206-13. PubMed ID: 23887603 [TBL] [Abstract][Full Text] [Related]
14. The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8 Puca E; Probst P; Stringhini M; Murer P; Pellegrini G; Cazzamalli S; Hutmacher C; Gouyou B; Wulhfard S; Matasci M; Villa A; Neri D Int J Cancer; 2020 May; 146(9):2518-2530. PubMed ID: 31374124 [TBL] [Abstract][Full Text] [Related]
15. Antibody-mediated delivery of interleukin 4 to the neo-vasculature reduces chronic skin inflammation. Hemmerle T; Zgraggen S; Matasci M; Halin C; Detmar M; Neri D J Dermatol Sci; 2014 Nov; 76(2):96-103. PubMed ID: 25190364 [TBL] [Abstract][Full Text] [Related]
16. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation. Frey K; Zivanovic A; Schwager K; Neri D Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052 [TBL] [Abstract][Full Text] [Related]
17. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. Frey K; Schliemann C; Schwager K; Giavazzi R; Johannsen M; Neri D J Urol; 2010 Dec; 184(6):2540-8. PubMed ID: 21030045 [TBL] [Abstract][Full Text] [Related]
18. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649 [TBL] [Abstract][Full Text] [Related]
19. Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12. Sommavilla R; Pasche N; Trachsel E; Giovannoni L; Roesli C; Villa A; Neri D; Kaspar M Protein Eng Des Sel; 2010 Aug; 23(8):653-61. PubMed ID: 20551083 [TBL] [Abstract][Full Text] [Related]
20. The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. Schwager K; Hemmerle T; Aebischer D; Neri D J Invest Dermatol; 2013 Mar; 133(3):751-758. PubMed ID: 23096716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]